Research progress in correlations between epithelial-mesenchymal transition and hepatic fibrosis

doi:10.19803/j.1672-8629.20230536

Abstract

Abstract: Hepatic fibrosis is a pathophysiological process, which refers to abnormal hyperplasia of hepatic connective tissue caused by various pathogenic factors. Any liver injury undergoes liver fibrosis in the process of liver repair and healing. As long as injury persists, fibrosis will evolve into cirrhosis or even liver cancer. Therefore, it is of great significance to reverse liver fibrosis. In recent years, increasing research has been conducted on epithelial mesenchymal transition that has been found to occur in liver fibrosis, which is why reversing epithelial mesenchymal transition is one of the mechanisms for reversing liver fibrosis. This paper reviews the cell types of epithelial mesenchymal transition in hepatic fibrosis, the mechanism of epithelial mesenchymal transition-related signaling pathways in hepatic fibrosis, and the non-coding RNAs that affects hepatic fibrosis through epithelial mesenchymal transition in order to provide data the research and treatment of hepatic fibrosis.

Key words: epithelial-mesenchymal transition, hepatic fibrosis, liver cancer, signal transduction pathway, non-coding RNA, reverse

CLC Number:

R977

LI Mingqi, ZHAO Xiaolu, GAO Xiaoyang, MA Yuehong. Research progress in correlations between epithelial-mesenchymal transition and hepatic fibrosis[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 464-468.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230536

https://www.zgywjj.com/EN/Y2024/V21/I4/464

References

[1] ZHANG WF, WANG ZC.Research overview of the molecular mechanism of traditional Chinese medicine in the treatment of liver fibrosis[J]. China Journal of Traditional Chinese Medicine(中华中医药学刊), 2022, 40(12): 119-124.
[2] KISSELEVA T, BRENNER D.Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166.
[3] FRIEDMAN SL, PINZANI M.Hepatic fibrosis 2022: unmet needs and a blueprint for the future[J]. Hepatology, 2022, 75(2): 473-488.
[4] CHEN Y, FAN Y, GUO DY, et al.Study on the relationship between hepatic fibrosis and epithelial-mesenchymal transition in intrahepatic cells[J]. Biomed Pharmacother, 2020, 129: 110413.
[5] MANFIOLETTI G, FEDELE M.Epithelial-mesenchymal transition (EMT) 2021[J]. International Journal of Molecular Sciences, 2022, 23(10): 58-48.
[6] MARCONI GD, FONTICOLI L, RAJAN TS, et al.Epithelial-Mesenchymal Transition (EMT): the type-2 EMT in wound healing, tissue regeneration and organ fibrosis[J]. Cells, 2021, 10(7): 1587.
[7] BAGHAEI K, MAZHARI S, TOKHANBIQLI S, et al.Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis[J]. Drug Discovery Today, 2022, 27(4): 1044-1061.
[8] KAMM DR, MCCOMMIS KS.Hepatic stellate cells in physiology and pathology[J]. J Physiol, 2022, 600(8): 1825-1837.
[9] TSUCHIDA T, FRIEDMAN SL.Mechanisms of hepatic stellate cell activation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(7): 397-411.
[10] RIVEDI P, WANG S, FRIEDMAN SL.The power of plasticity-metabolic regulation of hepatic stellate cells[J]. Cell Metab, 2021, 33(2): 242-257.
[11] KONG D, ZHANG Z, CHEN L, et al.Curcumin blunts epithelial-mesenchymal transition of hepatocytes to alleviate hepatic fibrosis through regulating oxidative stress and autophagy[J]. Redox Biol, 2020, 36: 101600.
[12] SONG L, CHEN TY, ZHAO XJ, et al.Pterostilbene prevents hepatocyte epithelial-mesenchymal transition in fructose-induced liver fibrosis through suppressing miR-34a/Sirt1/p53 and TGF-β₁/Smads signalling[J]. Br J Pharmacol, 2019, 176(11): 1619-1634.
[13] ZHAO YL, ZHU RT, SUN YL.Epithelial-mesenchymal transition in liver fibrosis[J]. Biomed Rep, 2016, 4(3): 269-274.
[14] FAN J, WANG Q, ZHANG Z, et al.Curcumin mitigates the epithelial-to-mesenchymal transition in biliary epithelial cells through upregulating CD109 expression[J]. Drug Dev Res, 2019, 80(7): 992-999.
[15] CHILVERY S, BANSOD S, SAIFI MA, et al.Piperlongumine attenuates bile duct ligation-induced liver fibrosis in mice via inhibition of TGF-β₁/Smad and EMT pathways[J]. Int Immunopharmacol, 2020, 88: 106909.
[16] HU HH, CHEN DQ, WANG YN, et al.New insights into TGF-β/Smad signaling in tissue fibrosis[J]. Chem Biol Interact, 2018, 292: 76-83.
[17] CHEN Y, FAN Y, GUO DY, et al.Study on the relationship between hepatic fibrosis and epithelial-mesenchymal transition in intrahepatic cells[J]. Biomed Pharmacother, 2020, 129: 110413.
[18] SUN S, XIE F, ZHANG Q, et al.Advanced oxidation protein products induce hepatocyte epithelial-mesenchymal transition via a ROS-dependent, TGF-β/Smad signaling pathway[J]. Cell Biol Int, 2017, 41(8): 842-853.
[19] SHU G, DAI C, YUSUF A, et al.Limonin relieves TGF-β-induced hepatocyte EMT and hepatic stellate cell activation in vitro and CCl₄-induced liver fibrosis in mice via upregulating Smad7 and subsequent suppression of TGF-β/Smad cascade[J]. J Nutr Biochem, 2022, 107: 109039.
[20] PARK JH, YOON J, LEE KY, et al.Effects of geniposide on hepatocytes undergoing epithelial-mesenchymal transition in hepatic fibrosis by targeting TGFβ/Smad and ERK-MAPK signaling pathways[J]. Biochimie, 2015, 113: 26-34.
[21] PARK JH, PARK B, PARK KK.Suppression of hepatic epithelial-to-mesenchymal transition by melittin via blocking of TGFβ/Smad and MAPK-JNK signaling pathways[J]. Toxins (Basel), 2017, 9(4): 138.
[22] XIONG PP, LIU F.Research progress on the role of epithelial-mesenchymal transition-related signaling pathways in liver fibrosis[J]. International Journal of Digestive Diseases(国际消化病杂志), 2016, 36(3): 153-155, 196.
[23] ZHANG TT, YAN YB, YE L, et al.Hedgehog pathway-mediated epithelial-mesenchymal transition promotes CCl₄-induced liver fibrosis in rats[J]. Journal of Zhejiang University of Traditional Chinese Medicine(浙江中医药大学学报), 2021, 45(4): 345-352.
[24] ZHANG W, WAN YP, ZHU X.Research progress of Notch signaling pathway in liver fibrosis[J]. Tianjin Medicine(天津医药), 2021, 49(7): 773-777.
[25] PAN Y, ZHANG QD, FANG FM, et al.The role of Notch signal transduction pathway in the activation of primary hepatic stellate cells in vitro[J]. Chinese Journal of Hepatology(Electronic Edition)(中国肝脏病杂志电子版), 2018, 10(3): 66-72.
[26] WANG YJ, XIE XL, JIANG HQ.Research progress on regulation of epithelial-mesenchymal transition in liver fibrosis and targeted therapy[J]. Journal of Clinical Hepatobiliary Diseases(临床肝胆病杂志), 2021, 37(1): 165-168.
[27] ZHANG SW, YU XQ, CHEN F, et al.Research progress on the role of Wnt signaling pathway in hepatic stellate cell activation[J]. Shandong Medicine(山东医药), 2019, 59(19): 98-101.
[28] MCCUBREY JA, RAKUS D, GIZAK A, et al.Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-diverse effects on cell growth, metabolism and cancer[J]. Biochim Biophys Acta, 2016, 1863(12): 2942-2976.
[29] ZHU Y, TAN J, XIE H, et al.HIF-1α regulates EMT via the Snail and β-catenin pathways in paraquat poisoning-induced early pulmonary fibrosis[J]. J Cell Mol Med, 2016, 20(4): 688-697.
[30] YANG X, DU X, SUN L, et al.SULT2B1b promotes epithelial-mesenchymal transition through activation of the β-catenin/MMP7 pathway in hepatocytes[J]. Biochem Biophys Res Commun, 2019, 510(4): 495-500.
[31] LI Y, CHEN R, MENG ZP, et al.Research progress on the involvement of microRNAs in the regulation of liver fibrosis[J]. Medical Review(医学综述), 2021, 27(21): 4177-4182.
[32] ZHANG CY, YAN YX, LIANG J, et al.Research progress on the role of long non-coding RNA in liver fibrosis[J]. PLA Medical Journal(解放军医学杂志), 2021, 46(2): 186-192.
[33] ZHU J, LUO Z, PAN Y, et al.H19/miR-148a/USP4 axis facilitates liver fibrosis by enhancing TGF-β signaling in both hepatic stellate cells and hepatocytes[J]. J Cell Physiol, 2019, 234(6): 9698-9710.
[34] ZHENG J, YU F, DONG P, et al.Long non-coding RNA PVT1 activates hepatic stellate cells through competitively binding microRNA-152[J]. Oncotarget, 2016, 7(39): 62886-62897.
[35] GHAFOURI-FARD S, ABAK A, TALEBI SF, et al.Role of miRNA and lncRNAs in organ fibrosis and aging[J]. Biomed Pharmacother, 2021, 143: 112132.
[36] ZHANG K, ZHANG M, YAO Q, et al.The hepatocyte-specifically expressed lnc-HSER alleviates hepatic fibrosis by inhibiting hepatocyte apoptosis and epithelial-mesenchymal transition[J]. Theranostics, 2019, 9(25): 7566-7582.
[37] YU F, GENG W, DONG P, et al.LncRNA-MEG3 inhibits activation of hepatic stellate cells through SMO protein and miR-212[J]. Cell Death Dis, 2018, 9(10): 1014.
[38] DENG Y, LI J, ZHOU M, et al.C-Myc affects hedgehog pathway via KCNQ1OT1/RAC1: a new mechanism for regulating HSC proliferation and epithelial-mesenchymal transition[J]. Dig Liver Dis, 2021, 53(11): 1458-1467.
[39] PAN Y, WANG J, HE L, et al. MicroRNA-34a promotes EMT and liver fibrosis in primary biliary cholangitis by regulating TGF-β₁/smad pathway[J/OL]. J Immunol Res, (2021-04-23)[2024-02-22]. https://www.hindawi.com/journals/jir/2021/6890423/.
[40] WU K, YE C, LIN L, et al.Inhibiting miR-21 attenuates experimental hepatic fibrosis by suppressing both the ERK1 pathway in HSC and hepatocyte EMT[J]. Clin Sci (Lond), 2016, 130(16): 1469-1480.
[41] LANG Z, LI Y, LIN L, et al.Hepatocyte-derived exosomal miR-146a-5p inhibits hepatic stellate cell EMT process: a crosstalk between hepatocytes and hepatic stellate cells[J]. Cell Death Discov, 2023, 9(1): 304.
[42] ZHENG J, WANG W, YU F, et al.MicroRNA-30a suppresses the activation of hepatic stellate cells by inhibiting epithelial-to-mesenchymal transition[J]. Cell Physiol Biochem, 2018, 46(1): 82-92.
[43] CHENG B, ZHU Q, LIN W, et al.MicroRNA-122 inhibits epithelial-mesenchymal transition of hepatic stellate cells induced by the TGF-β₁/Smad signaling pathway[J]. Exp Ther Med, 2019, 17(1): 284-290.
[44] LIANG Z, LI J, ZHAO L, et al.MiR375 affects the hedgehog signaling pathway by downregulating RAC1 to inhibit hepatic stellate cell viability and epithelialmesenchymal transition[J]. Mol Med Rep, 2021, 23(3): 182.